Each year MTF Biologics awards major grants to applicants selected through a peer review process which provides financial assistance to new and on-going research projects. Scientific grants are awarded to researchers at accredited institutions in support of innovation in allograft transplantation.
For questions regarding the MTF Biologics Grant Program, please contact Jeffrey Cartmell, Ph.D., Sr. Director, Intellectual Property and Grants, at jeffrey_cartmell@mtf.org or (732) 661-2151. For questions of an administrative nature, please contact Christine Jenkins, Grants Administrator, at christine_jenkins@mtf.org or (732) 661-2159.
As a nonprofit organization, MTF Biologics reinvests to positively affect lives across the globe by offering Allograft Innovation Grants for funding translational and clinical research to advance Allograft Tissue Transplantation and support our mission to Save and Heal Lives. Funding is available for both Allograft Translational Research and Allograft Clinical Research projects. Awarded grants are aimed at advancing allograft tissue transplantation science and patient care. Submitted research projects must utilize allografts or allograft-derived materials, and must have a strong clinical translation component.
Clinical areas of interest include: Orthopedics, Spine, Sports Medicine, Plastic & Reconstructive Surgery, Aesthetics, Surgical Soft Tissue Repair and Reconstruction, Wound Care, or other areas which utilize allograft transplant technologies.
Proposed studies should focus on innovative translational and clinical research in the fields of tissue allograft transplantation and science, novel uses of allografts, combination with other biomaterials to enhance properties, and transformative regenerative medicine technologies relying on allograft tissues and matrices.
Interested applicants can apply to one of the following tracks: Junior Investigator, Established Investigator, or Career Development.
We are not currently accepting grant applications. The next grant application cycle will open in 2025.